Biocryst Pharmaceuticals Share Price Today
(NASDAQ: BCRX)

Name: Biocryst Pharmaceuticals Share Price Today (NASDAQ: BCRX) - Biocryst Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biocryst Pharmaceuticals share price is $7.4 & ₹632.44 as on 18 Apr 2025, 2.30 'hrs' IST

$7.4

▲

0.18

(2.49%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Biocryst Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Biocryst Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biocryst Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Biocryst Pharmaceuticals share price movements

Today's Low: $7.18
Today's High: $7.51
$7.40
3.04%
Downside
Day's Volatility :4.4%
Upside
1.4%
52 Weeks Low: $4.03
52 Weeks High: $9.50
$7.40
45.54%
Downside
52 Weeks Volatility :57.58%
Upside
22.11%

Biocryst Pharmaceuticals (BCRX) Returns

Period	Biocryst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.76%	-2.8%	0.0%
6 Months	-1.6%	-11.0%	0.0%
1 Year	67.04%	-1.9%	0.0%
3 Years	-23.63%	-1.5%	-12.9%

Biocryst Pharmaceuticals (BCRX) Key Statistics

in dollars & INR

Previous Close	$7.22
Open	$7.17
Today's High	$7.505
Today's Low	$7.175
Market Capitalization	$1.5B
Today's Volume	$3.4M
52 Week High	$9.5
52 Week Low	$4.03
Revenue TTM	$450.7M
EBITDA	$1.7M
Earnings Per Share (EPS)	$-0.43
Profit Margin	-19.72%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1925.37%

How to invest in Biocryst Pharmaceuticals Stock (BCRX) from India?

It is very easy for Indian residents to invest directly in Biocryst Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biocryst Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biocryst Pharmaceuticals or BCRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biocryst Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biocryst Pharmaceuticals shares which would translate to 0.115 fractional shares of Biocryst Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biocryst Pharmaceuticals, in just a few clicks!

Returns in Biocryst Pharmaceuticals (BCRX) for Indian investors in Rupees

The Biocryst Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Biocryst Pharmaceuticals investment value today

Current value as on today

₹1,69,384

Returns

₹69,384

(+69.38%)

Returns from Biocryst Pharmaceuticals Stock

₹67,043 (+67.04%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Biocryst Pharmaceuticals (BCRX)

-29%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Biocryst Pharmaceuticals Stock from India on INDmoney has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Biocryst Pharmaceuticals

FMR Inc
0.37%

Analyst Recommendation on Biocryst Pharmaceuticals

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals(by analysts ranked 0 to 5 stars)

Analyst Forecast on Biocryst Pharmaceuticals Stock (BCRX)

What analysts predicted

Upside of 99.02%

Target:

$14.73

Current:

$7.40

Insights on Biocryst Pharmaceuticals Stock (Ticker Symbol: BCRX)

Price Movement
In the last 1 year, BCRX stock has moved up by 63.0%
Increasing Revenue
Revenue is up for the last 4 quarters, 92.76M → 131.53M (in $), with an average increase of 10.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -12.67M → -26.79M (in $), with an average decrease of 50.8% per quarter

Biocryst Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Biocryst Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Biocryst Pharmaceuticals (BCRX) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biocryst Pharmaceuticals Inc	-6.11%	-1.6%	67.04%	-23.63%	113.26%
Haleon Plc Spon Ads	-2.21%	2.4%	24.33%	37.92%	37.92%
United Therapeutics Corporation	-9.06%	-23.17%	19.67%	49.68%	60.12%
Zoetis Inc.	-10.05%	-21.53%	1.48%	-20.83%	16.7%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biocryst Pharmaceuticals Inc	NA	NA	-0.28	-0.05	-19.25	0.0	NA	-2.28
Haleon Plc Spon Ads	24.33	24.33	1.8	0.41	0.09	0.05	0.02	1.79
United Therapeutics Corporation	11.56	11.56	1.43	27.16	0.19	0.12	NA	143.74
Zoetis Inc.	27.18	27.18	2.63	6.09	0.51	0.15	0.01	10.64

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biocryst Pharmaceuticals Inc	Buy	$1.5B	113.26%	NA	-19.72%
Haleon Plc Spon Ads	Buy	$46.1B	37.92%	24.33	12.84%
United Therapeutics Corporation	Buy	$12.8B	60.12%	11.56	41.53%
Zoetis Inc.	Buy	$66.3B	16.7%	27.18	26.86%

About Biocryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Organization	Biocryst Pharmaceuticals
Employees	580
CEO	Mr. Jon P. Stonehouse
Industry	Health Technology

Management People of Biocryst Pharmaceuticals

Name	Title
Mr. Jon P. Stonehouse	CEO, President & Executive Director and Interim CFO, Principal Accounting Officer
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer
Mr. John D. Bluth	Chief Communications Officer
Ms. Stephanie Angelini	Chief People Officer
Dr. William P. Sheridan MBBS	Chief Development Officer
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer
Mr. Philip George	Chief Strategy Officer

Important FAQs about investing in BCRX Stock from India :

What is Biocryst Pharmaceuticals share price today?

Biocryst Pharmaceuticals share price today stands at $7.40, Open: $7.17 ; Previous Close: $7.22 ; High: $7.51 ; Low: $7.18 ; 52 Week High: $9.50 ; 52 Week Low: $4.03.

The stock opens at $7.17, after a previous close of $7.22. The stock reached a daily high of $7.51 and a low of $7.18, with a 52-week high of $9.50 and a 52-week low of $4.03.

Can Indians buy Biocryst Pharmaceuticals shares?

Yes, Indians can invest in the Biocryst Pharmaceuticals (BCRX) from India.

With INDmoney, you can buy Biocryst Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biocryst Pharmaceuticals at zero transaction cost.

How can I buy Biocryst Pharmaceuticals shares from India?

It is very easy to buy Biocryst Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biocryst Pharmaceuticals (BCRX) be purchased?

Yes, you can buy fractional shares of Biocryst Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Biocryst Pharmaceuticals stocks?

To start investing in Biocryst Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.